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Abstract
Abnormal patterns of DNA methylation are observed in several types of human cancer. While localized DNA methylation of
CpG islands has been associated with gene silencing, the effect that genome-wide loss of methylation has on tumorigenesis
is not completely known. To examine its effect on tumorigenesis, we induced DNA demethylation in a rat model of human
chondrosarcoma using 5-aza-2-deoxycytidine. Rat specific pyrosequencing assays were utilized to assess the methylation
levels in both LINEs and satellite DNA sequences following 5-aza-2-deoxycytidine treatment. Loss of DNA methylation was
accompanied by an increase in invasiveness of the rat chondrosarcoma cells, in vitro, as well as by an increase in tumor
growth in vivo. Subsequent microarray analysis provided insight into the gene expression changes that result from 5-aza-2-
deoxycytidine induced DNA demethylation. In particular, two genes that may function in tumorigenesis, sox-2 and midkine,
were expressed at low levels in control cells but upon 5-aza-2-deoxycytidine treatment these genes became overexpressed.
Promoter region DNA analysis revealed that these genes were methylated in control cells but became demethylated
following 5-aza-2-deoxycytidine treatment. Following withdrawal of 5-aza-2-deoxycytidine, the rat chondrosarcoma cells
reestablished global DNA methylation levels that were comparable to that of control cells. Concurrently, invasiveness of the
rat chondrosarcoma cells, in vitro, decreased to a level indistinguishable to that of control cells. Taken together these
experiments demonstrate that global DNA hypomethylation induced by 5-aza-2-deoxycytidine may promote specific
aspects of tumorigenesis in rat chondrosarcoma cells.
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Introduction
Aberrant DNA methylation is thought to play an integral role in
the complex process of tumorigenesis [1]. Abnormal hypermethy-
lation may result in the silencing of genes that are members of
pathways ranging from cell division to tumor suppression.
Reintroducing the expression of abnormally silenced genes may
restore control of these various signaling and regulatory pathways.
Current epigenetic therapies are aimed at bringing on
hypomethylation with the goal of reverting hypermethylation-
induced gene silencing [2]. One such therapeutic agent is 5-Aza-2-
deoxycytidine, which is a deoxycytidine analog that becomes
incorporated into DNA and inhibits the activity of DNA
methyltransferases [3,4]. The incorporation of 5-Aza-2-deoxycy-
tidine and subsequent inhibition of DNA methyltransferases results
in reduced levels of DNA methylation [5,6]. 5-Aza-2-deoxycyti-
dine has been shown to have clinical benefits in the treatment of
myelodysplastic syndrome and it has also been shown to be
effective in the treatment of other myeloid malignancies [7].
Despite the potential benefits of 5-aza-2-deoxycytidine, the
complete ramifications of treating tumor cells with a global DNA
hypomethylating agent are unknown. The phenomenon of global
DNA hypomethylation has been observed in several types of
cancer [8], and DNA hypomethylation has also been associated
with tumor aggressiveness [9]. Evidence also suggests that DNA
hypomethylation may play a causal role in tumorigenesis [10,11].
To study the impact of global DNA hypomethylation on the
behavior of tumor cells we treated swarm rat chondrosarcoma
(SRC) cells with 5-aza-2-deoxycytidine and monitored its effect
both in vitro and in vivo. We selected the SRC tumor model based
on its extensive characterization and the ability of the SRC cells to
be grown and studied both in vitro and in vivo [12,13,14,15,16].
SRC cells were treated in vitro with a low dose of 5-Aza-2-
deoxycytidine for 30 days to induce genome-wide hypomethyla-
tion and their level of methylation was assessed using rat specific
pyrosequencing assays. Treatment with 5-Aza-2-deoxycytidine led
to demethylation of both LINE and microsatellite regions
throughout the genome. The effects of long-term exposure to
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concern is that such treatment may lead to the expression of genes
that are normally epigenetically silenced. In addition, it may cause
illegitimate transcription events [17,18]. Indeed, invasion assays
performed with treated and untreated SRC cells indicated that loss
of methylation is accompanied by an increase in invasiveness.
Furthermore, microarray analysis revealed that 5-Aza-2-deoxycy-
tidine treatment leads to alterations in expression of several
developmentally regulated genes.
Based on their differential expression, two of these genes,
midkine and sox-2, were selected for additional expression and
epigenetic analyses. Midkine, a growth factor [19], and sox-2, a
pluripotent transcription factor [20], are expressed at higher levels
following 5-Aza-2-deoxycytidine treatment. Treatment with 5-
Aza-2-deoxycytidine leads to loss of methylation in the promoter
regions of both midkine and sox-2 genes, thus suggesting that
methylation may play a role in the transcriptional regulation of
these genes.
Since 5-Aza-2-deoxycytidine-induced hypomethylation resulted
in several phenotypic changes in the SRC cells in vitro, we wanted
to determine if the treatment would affect cell growth in vivo.
Following subcutaneous transplantation, the 5-Aza-2-deoxycyti-
dine treated SRC cells formed larger tumors than the correspond-
ing untreated SRC cells. Methylation and expression analyses of
the in vivo SRC cells revealed that the effect of 5-Aza-2-
deoxycytidine could be observed for at least 60 days following
treatment discontinuation.
Altogether the in vivo and in vitro results suggest that induction of
genome-wide hypomethylation by 5-Aza-2-deoxycytidine results
in an increase in the tumorigenicity of the SRC cells. The SRC
experiments also highlight the importance that epigenetic
modifications may have in cancer and suggest that DNA
hypomethylation may have a functional role in tumor progression.
Materials and Methods
Ethics Statement
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and/or local animal
welfare bodies, and all animal work was approved by the
Institutional Animal Care and Use Committee (Children’s
Memorial Research Center; protocol IACUC #2006-30).
Establishment of a Bioluminescent Rat Chondrosarcoma
Cell Line
A Murine Stem Cell Virus-Luciferase-Internal ribosomal entry
site-Hygromycin (MSCV-Luc-I-Hygro) retroviral vector was
prepared by transfecting 293T cells with three plasmids;
pMSCV-Luc-I-Hyrgo (which encodes the Luciferase and hygro-
mycin phosphotransferase), pEQ-Pam3(-E) (which encodes retro-
viral gag and pol) and pSRa-G (which encodes glycoprotein G
from Vesicular Stomatitis Virus) [21]. Forty-eight hours post-
transfection media containing retroviral vector was collected,
aliquoted, frozen, and stored at 280uC. This vector was then used
to transduce the Swarm rat chondrosarcoma cell line (SRC-LTC
(Long Term Culture) [13], [obtained from Jeff W. Stevens,
University of Iowa]), in the presence of 5 mg/ml polybrene on
three successive days allowing the cells to recover in the media
generally used overnight. Transduced cells were selected by
incubation with hygromycin B (Sigma-Aldrich, St. Louis, MO) at a
concentration of 500 mg/ml for 14 days. Once the hygromycin
resistant population was established, the cells were maintained in
media containing 500 mg/ml of hygromycin B. The newly
established rat chondrosarcoma cell line was named SRC-
MSCV3-LTC.
Cell Culture Conditions and 5-Aza-2-Deoxycytidine
Treatment
SRC-MSCV3-LTC cells were cultured in DMEM high glucose
(4.5 g glucose/ml) supplemented with 10% FBS and Penicillin/
Streptomycin. Cells were plated at 2.5.610
4 cells with 6 ml of
media in a 25 cm
2 T flask. Cells were grown until they became
80–90% confluent (6 days), and at this time the cells were
trypsinized/split and plated as described. For the 5-Aza-2-
deoxycytidine treatment, the media was supplemented with
0.1 uM 5-Aza-2-deoxycytidine on the day that the cells were
passaged. Cell viability was assessed 72 hours and 144 hours
following 5-Aza-2-deoxycytidine treatment (0.1, 0.3, 1.0, 3.0, 10,
30, 100, and 300 mM). For the 72-hour treatment, the cells were
treated with 5-Aza-2-deoxycytidine at day 0 and 72 hours later the
viability was examined (Figure S1A). For the 144-hour treatment,
cells were treated with 5-Aza-2-deoxycytidine every 24 hours
without changing the media as previously described [22], and
144 hours after the initial treatment the viability was examined
(Figure S1B). Viability was determined using the Guava EasyCyte
Mini Flow Cytometry System, and the Guava ViaCount Reagent
(Millipore; cat no. 4000-0040).
The Swarm rat chondrosarcoma line SRC-MSCV3-LTC, was
treated with 0.1 uM 5-Aza-2-deoxycytidine for 5 passages
(30 days). Control cells were grown for 5 passages without 5-
Aza-2-deoxycytidine. After 5 passages, cells were either frozen for
subsequent DNA and RNA analysis, or they were passaged for five
additional passages (30 days) without any drug treatment after
which they were frozen for future analysis.
For in vivo experiments, cells were grown in vitro for 5 passages
with or without 5-Aza-2-deoxycytidine. For the treated cells, the 5-
Aza-2-deoxycytidine treatment was removed on the day of the
injection and the cells did not receive further 5-Aza-2-deoxycy-
tidine treatment.
Tumor Inductions
Following growth for 5 passages, cells were injected subcutane-
ously into the lower lumbar region of 4 week old nude mice(Males;
Charles River, Strain code: 088). The SRC cells were grown until
they were 80% confluent, the cells were then washed with PBS,
and then cells were removed from the plate using TrypLE Express
(GIBCO cat#: 12605-010) according to manufactures instruc-
tions. Following removal of SRC cells from plates, the cells were
washed with PBS, centrifuged, and resuspended in PBS. Either
1610
6,5 610
6,o r1 0 610
6 cells were injected subcutaneously. For
each experiment one animal was injected with untreated control
SRC cells, and one animal was injected with 5-Aza-2-deoxycyti-
dine treated cells. The animals did not receive any dose of 5-Aza-
2-deoxycytidine.
Following the injection, the animals were monitored twice
weekly for 60 days. After 60 days the animals were euthanized by
CO2 gas inhalation followed by cervical dislocation. Immediately
following euthanization, tumors and other tissues were frozen in
liquid nitrogen or placed in paraformaldehyde for histology.
In Vivo Imaging
All in vivo imaging was performed with the Xenogen IVIS 200
imaging system. Ten minutes prior to imaging, D-luciferin
(150 mg/kg of body weight) was injected into the intraperitoneal
cavity of the mice. During the image acquisition animals were
anesthetized with isoflurane inhalation at 1 to 2%.
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Rat genome sequence (rn4/version 3.4, Nov. 2004) and the
annotation for repetitive elements were obtained from the UCSC
Genome Database. Based on genomic co-ordinates of LINE
elements provided by the UCSC database, 899,092 LINE
sequences were extracted and subjected to in silico bisulfite
treatment. 8,460 L1 elements with length over 6000 bp were
identified and used for alignment to generate LINE nucleotide
base matrix. A region within L1 elements with dense CpG
dinucleotides was selected for PCR primer design. An electronic
PCR was performed with the novel primers designed for rat
LINEs. 827 LINE elements in the rat genome would be targeted in
PCR reactions with the primer set designed. With two sequencing
primers, a total number of 7 CpG dinucleotides were sequenced
for each LINE element targeted. The global methylation data
generated was derived from a minimum number of 5,700 CpG
dinucleotides in LINE elements. A similar approach was taken to
design novel primers for rat satellite repeats. Primers targeting a
minimum number of 137 distinct Satellite I elements and five
distinct Satellite II elements were designed. For each Satellite
element targeted, the methylation profiles were determined for
three CpG dinucleotides. Primer sequence and reaction conditions
are available in Table S1.
Microarray
Microarray analysis was used to examine the gene expression
profiles of the SRC cells (+)o r( 2)5-Aza-2-deoxycytidine
treatment. Microarray was carried out using the NimbleGen
microarray service. The Rattus norvegicus 1-plex array (14 probes/
target; 26739 genes; cat#: A6184-00-01) was used for each
hybridization. Two hybridizations were performed on 5-Aza-2-
deoxycytidine treated SRC cells and three hybridizations were
performed on untreated control SRC cells. Data were processed
and displayed using Genespring software (Agilent Technologies).
Genespring was used to identify differentially expressed genes that
had a 5-fold difference between the 5-Aza-2-deoxycytidine treated
samples and the untreated control samples. Additionally, Gene-
spring was used to create a gene tree (Pearson coefficient) to
graphically represent the data.
The list of differentially expressed genes was analyzed using a
pathway-mapping program (Ingenuity Pathway Analysis version
7.0). Ingenuity was used to sort the list of differentially expressed
genes (977genes) based on their role in cellular function and
disease. Ingenuity identified 135 cancer related genes. For the heat
map, the cancer gene list was further filtered by requiring a
minimum expression level of at least 1,000 relative fluorescence
units in at least 2 different hybridizations.
Genespring was used for hierarchical clustering, to create a gene
tree (Pearson coefficient), and to generate the heat map used to
graphically represent the data.
The list of genes with a 5-fold difference (977genes) was also
analyzed using GeneGo to identify pathways that were altered
following 5-Aza-2-deoxycytidine treatment.
All presented microarray data is MIAME compliant. The raw
microarray data has been deposited in a MIAME compliant
database. The microarray data has been deposited at GEO (GEO
accession number: GSE17598).
Real-Time Quantitative PCR
Total RNA was isolated using Trizol; RNA was treated with
TURBO DNA-free (Ambion Cat# AM1907). Total RNA (1 mg)
was used to make cDNA with the iScript cDNA Synthesis kit
(BioRad). Rat Midkine real time PCR was performed with the iQ
SYBR Green Supermix (BioRad), and midkine rat specific primers
(Forward: CCCAAGATGTAACCCACCAG; Reverse: GCTCA-
CTTCCCAGAATCCC). For SYBR green PCR’s, 18S-RNA was
used as a reference gene [23] (Forward: GGGAGGTAGTG-
ACGAAAAATAACAAT; Reverse: TTGCCCTCCAATGGA-
TCCT).
Rat sox-2 real time PCR was performed with iQ Supermix
(biorad) using Roche universal probe #119 (cat. no.
04693531001) and rat specific primers(forward: ATTACCCG-
CAGCAAAATGAC and Reverse: TTTTTGCGTTAATTTG-
GATGG). For PCR’s with the Roche probes 18S-RNA was used
as a reference gene (Probe #22 (cat. no. 04686969001 with
primers: Forward: GGTGCATGGCCGTTCTTA; Reverse:
TCGTTCGTTATCGGAATTAACC).
The Pfaffl method was used to calculate the normalized gene
expression [24]. For each real time PCR analysis the individual
sample being examined was used as the test sample in the Pfaffl
method. The calibrator sample, for the Pfaffl method, was an
equal mixture of cDNA from SRC control cells and 5-Aza-2-
deoxycytidine SRC cells. All real time qPCR results are displayed
as a ratio of the target gene relative to the reference gene, in a
specific test sample, compared to the expression of the target gene
relative to the reference gene in the calibrator sample.
CpG Island Identification
CpG islands in were located by searching the midkine and sox-2
genes in BLAT [25]. Each CpG island was more closely examined
using ‘‘CpG Island Searcher’’ [26] and each island was classified
as either a high-CpG promoter, an intermediate CpG promoter,
or as a low-CpG promoter as previously described [27].
Analysis of DNA Methylation by Sequencing of Sodium
Bisulfite-Treated DNA
Genomic DNA was obtained by digestion with proteinase K
(Quiagen) followed by phenol/chloroform extraction, and was
subjected to sodium bisulfite treatment to modify unmethylated
cytosine to uracil using the ‘CpGenome
TM
DNA Modification Kit’
(Chemicon International, CA). Bissulfite-treated DNA was ampli-
fied by a nested-PCR protocol using the primers described in
Table S2. PCR was performed in a volume of 25 ml containing
PCR Buffer (Qiagen); 1.5 mM of MgCl2 (Qiagen); 200 mMo f
dNTPs (Invitrogen); 0.32 mM of each primer and 1 U of Hot Start
Taq Plus DNA Polymerase (Qiagen). The PCR conditions were:
94uC for 10 min, 94uC for 3 min, 48uC for 3 min, 72uC for
2 min, one cycle; 94uC for 3 min, 50uC for 3 min, 72uC for 2 min,
five cycles; and 94uC for 1 min, 52uC for 1 min, 72uC for 1 min,
35 cycles for the first reaction and the same annealing tempera-
tures (48u,5 0 u and 52uC) for the nested reaction. Amplified
products were purified using the Gel Purification Kit (Qiagen) and
were ligated to a vector using the TOPO TA Cloning Kit
(Invitrogen). Twenty-four positive clones were sequenced for each
sample using the vector’s forward and reverse primers. DNA
sequencing reactions were performed using the ‘DNA dRhoda-
mine Terminator Cycle Sequencing Ready reaction’ kit (Applied
Biosystems) and an ABI3730xl sequencer (Applied Biosystems)
according to the manufacturer’s instructions.
Invasion Assay
A Membrane Invasion Culture System (MICS) was used to
measure the in vitro invasiveness of all SRC cell lines as previously
described [28]. Briefly, a polycarbonate membrane with 10-um
pores was uniformly coated with a defined matrix. Both upper and
lower wells of the chamber were filled with RPMI. SRC cells were
seeded into upper wells at a concentration of 5610
5 cells per well.
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5% CO2, cells that had invaded through the basement membrane
were collected, stained, and counted by light microscopy [29].
Statistical Analysis
Analysis of Variance (ANOVA) or two-sample t-test was used to
analyze changes of DNA methylation level among different
treatment conditions for Line1-S1, Line1-S2, Satellites 1 and 2,
respectively. Tukey’s method or Dunnett method was used to
adjust p-values due to multiple comparisons in ANOVA analysis.
A linear regression method was applied to analyze tumor weight
between two tumor groups (SRC Control and SRC 5AZA) after
adjusting for the number of cells injected. Tumor weight and
number of cells were transformed using the logarithm so that data
distribution was appropriate for the analysis methods used.
We used 0.05 as the significance level for comparisons. SAS 9.1
and R software was used for data analysis and graphing.
Results
5-Aza-2-Deoxycytidine Induces Hypomethylation of
LINE1 and Satellites 1 and 2
Methylation levels of cytosines in CpG dinucleotides of
repetitive elements has been used as a surrogate marker for
genome-wide methylation [30],in this study, LINE (Long
Interspersed Element) 1 and Satellites 1 and 2 were selected as
surrogate methylation markers. Rat specific pyrosequencing assays
were designed to examine methylation levels of these repetitive
sequences throughout the genome. The pyrosequencing assays
were used to determine the methylation levels in untreated cells, in
cells treated with a low dose of 5-Aza-2-deoxycytidine, and in cells
that were treated with 5-Aza-2-deoxycytidine followed by an
additional recovery period without the drug (30 days).
The level of DNA methylation in LINE, Satellite 1 and Satellite
2 regions of SRC cells decreases following 5-Aza-2-deoxycytidine
treatment (Figure 1). The SRC cells were grown for 30 additional
days after removal of 5-Aza-2-deoxycytidine. Following withdraw-
al of the drug, methylation was restored to levels that were
indistinguishable from those of control cells based on the LINE1
and Satellite 2 assays (Figure 1). Methylation was partially restored
for Satellite 1, but it did not completely regain the level that was
observed in control cells. This result suggests that the demethyl-
ating effects of 5-Aza-2-deoxycytidine treatment may persist after
five additional passages (30 days) without the drug.
Invasion Assay
The invasiveness of the SRC cells increased 40% following
5-Aza-2-deoxycytidine treatment (Figure 2). Thirty days post-
removal of treatment, the invasive activity dropped to a level that
was indistinguishable from that of control cells. The invasion assays
demonstrated that 5-Aza-2-deoxycytidine-induced DNA hypo-
methylation leads to an increase in the in vitro invasiveness of SRC
cells, and that following withdrawal of the drug, the invasive activity
of the SRC cells returns to the levels observed for control cells.
Microarray Analysis
Based on the invasion assays it was hypothesized that the 5-Aza-
2-deoxycytidine may alter gene expression of the SRC cells.
Microarray analysis was carried out to identify changes in gene
expression in untreated and in treated cells. The expression level of
several genes increased after treatment with 5-Aza-2-deoxycyti-
dine (Figure 3). Data analysis revealed that 977 genes (603 genes
upregulated and 374 downregulated) exhibited a 5-fold expression
difference in the untreated and treated SRC cells (see Table S3 for
gene list). The pathway-mapping program, Ingenuity, was used to
analyze the group of genes with a 5-fold difference in expression
(See Table S4 for separate pathway analysis of up- and down
regulated genes). Ingenuity revealed that the differentially
expressed genes might play a role in several cancer-relevant
pathways (Table 1). The top pathway, Cancer (135 genes), was
selected for further analysis. A subset of the cancer related genes
with a 5-fold difference are shown in a heat map (Figure 3). As
illustrated by the heat map, 5-Aza-2-deoxycytidine treatment can
lead to the alterations in the expression of genes that may play a
role in different aspects of cancer, ranging from cell growth and
proliferation, to cell cycle control, and to cell death.
One potential explanation of the microarray results is that 5-
Aza-2-deoxycytidine treatment results in the derepression of genes
that were epigenetically silenced. As a result, we may observe an
increase or a decrease in expression (e.g. derepression of a negative
regulator). To examine this possibility, expression and methylation
analyses were performed on two of the cancer related genes
(Figures 4 and 5). The genes, midkine and sox-2, were selected on
the basis of their differential expression compared to control cells,
and because they have CpG islands in their promoter regions (we
have previously demonstrated that both sox-2 and midkine are not
expressed in the control tissue, normal rat articular cartilage, data
not shown; GEO: GSM25926). Midkine and sox-2 were also
selected because they are developmentally regulated genes, and
studies have indicated that these genes may play functional roles in
stem cells [31,32]. Therefore, we wanted to determine if 5-Aza-2-
deoxycytidine-induced DNA hypomethylation could lead to the
expression of stem cell related genes in the SRC cells.
Figure 1. Pyrosequencing of LINE and Satellite 1 and 2 in vitro.
For each experiment the methylation pattern was analyzed in SRC
untreated control cells (SRC-Control), SRC cells treated with 5-Aza-2-
deoxycytidine for 5 passages (SRC 5AZA), and in SRC cells that were
treated with 5-Aza-2-deoxycytidine for 5 passages and then allowed to
grow for 5 additional passages without treatment (SRC 5AZA-STOP).
Pyrosequencing assay: LINE1-S1; [2481 CpG’s], LINE1-S2; [3308 CpG’s];
Satellite I [15CpG’s], and Satellite II [411 CpG’s]. Treatment of MSCV3-
LTC chondrosarcoma cells with 5-Aza-2-deoxycytidine leads to demeth-
ylation that can be detected throughout the genome. Altered DNA
methylation patterns can be detected several weeks following removal
of 5-Aza-2-deoxycytidine treatment. Bars represent the average DNA
methylation % of three biologic replicates, and error bars represent the
standard deviation of these replicates. ‘*’ Indicates values that are
significantly different than the ‘‘SRC Control’’ sample (p,.05).
doi:10.1371/journal.pone.0008340.g001
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The increase in expression of midkine (Figure 4A) and sox-2
(Figure 5A), following exposure to 5-Aza-2-deoxycytidine, was
confirmed by real-time quantitative RT-PCR. The expression of
each midkine and sox-2 decreased to a level that is slightly higher
than that of control cells thirty days following discontinuation of
5-Aza-2-deoxycytidine treatment. These data suggest that midkine
and sox-2 expression increases as a result of exposure to 5-Aza-2-
deoxycytidine, and that 30 days after discontinuation of 5-Aza-2-
deoxycytidine in vitro, the expression of these genes begins to
decrease. Although their expression level decreases, both midkine
and sox-2 areexpressed at levelsthat arehigher than thoseobserved
in untreated control cells (Figures 4A and 5A). This suggests that
SRC cells may continue to express midkine and sox-2 at high levels
for at least 30 days following removal of 5-Aza-2-deoxycytidine.
Both midkine and sox-2 contain CpG islands at their
transcription start sites. The CpG islands in the promoters of
midkine and sox-2 can be classified as intermediate CpG islands,
which is relevant because the activity of promoters containing
intermediate CpG islands correlates negatively with their meth-
ylation status [27]. Additionally, intermediate CpG islands may be
preferential targets for de novo methylation in somatic cells during
development [27].
The methylation statuses of both midkine and sox-2 CpG
islands were examined using bisulfite sequencing (Figures 4B and
5B). Two CpG islands were identified in the rat midkine gene.
One CpG island encompasses the midkine transcriptional start site
and the other is slightly downstream from it (Figure 4A). Both
midkine CpG islands were heavily methylated in untreated SRC
cells, and they became hypomethylated in 5-Aza-2-deoxycytidine
treated cells (Figure 4B).
Two CpG islands were also examined for sox-2 (Figure 5A).
The CpG island encompassing the sox-2 transcriptional start site
(CpG 154) was not methylated in either control or treated cells
(Figure S4). However, a CpG island (CpG 47) located less than
1 kb upstream of the sox-2 transcriptional start site was methylated
in untreated SRC cells. Following 5-Aza-2-deoxycytidine, this
CpG island became hypomethylated (Figure 5B).
These results suggest that 5-Aza-2-deoxycytidine treatment can
lead to the demethylation of CpG islands at or near the
transcriptional start site of midkine (Figures 4B) and sox-2 genes
(Figure 5B). The decrease in CpG island methylation was
accompanied by an increase in the expression of sox-2 and
midkine (Figures 4A and 5A), consistent with the hypothesis that
methylation may play a role in the regulation of these genes.
In Vivo Tumor Formation
SRC cells were transplanted into nude mice to test tumorige-
nicity following 5-Aza-2-deoxycytidine-induced DNA hypomethy-
lation. The SRC cell line used for all aforementioned experiments
stably expresses luciferase, which enables tumor growth to be
examined in vivo. SRC cells treated with 5-Aza-2-deoxycytidine
produced larger tumors than those induced with control SRC cells
(Figure 6A and 6B).
Subcutaneous tumors were induced with 1610
6,5 610
6,7 610
6,
or 10610
6 cells. In preparation for injections, SRC cells were
treated in vitro for 30 days with 5-Aza-2-deoxycytidine, after which
the treatment was stopped and the cells were transplanted into
nude mice. Control tumors were induced with untreated SRC
cells. Tumors were resected sixty days after transplantation. As it
has been documented with human chondrosarcoma [33,34], the
SRC cells produced tumors with varying degrees of heterogeneity
(Figure 7A and 7B). Albeit relevant, histological grading is not
predictive of outcome [35], and no markers of prognostic value
have been identified to date for human chondrosarcoma [36].
Hence, we examined another characteristic of the tumor, tumor
weight, which demonstrated that 5-Aza-2-deoxycytidine treated
cells produced larger tumors than those derived from untreated
cells (Figure 6B and Table S5).
Histological analysis detected the presence of SRC cells in the
lungs of mice injected with control cells and in the lungs of mice
injected with 5-Aza-2-deoxycytidine treated cells (Table S5).
However, it should be noted that SRC cells were detected
macroscopically in the lungs of mice injected with 5-Aza-2-
deoxycytidine-treated cells (3 out of 9 mice; Figure S2). SRC cells
could not be detected macroscopically in the lungs of mice injected
with untreated control cells. These results indicated that 5-Aza-2-
deoxycytidine-treated SRC cells may grow more aggressively than
untreated SRC cells in the lung of subcutaneously injected mice.
Taken together, the in vivo analyses demonstrated that DNA
hypomethylation, induced by 5-Aza-2-deoxycytidine, led to the
formation of more aggressive tumors than the tumors formed from
untreated control SRC cells both locally, at the site of injection,
and distantly, in the lungs.
Methylation of SRC Cells In Vivo
The tumors derived from untreated SRC cells were more
methylated than the tumors derived from 5-Aza-2-deoxycytidine
treated cells (Figures 8). In vivo the 5-Aza-2-deoxycytidine treated
cells were injected and allowed to grow in vivo without treatment
for 60 days. After 60 days of growth in vivo, tumors derived from 5-
Aza-2-deoxycytidine-treated SRC cells exhibited a significantly
lower level of methylation (Figure 8; LINE-1, LINE1-S2, Satellite
1, and Satellite 2) than that of the tumors derived from untreated
control cells. This result is of note since in vitro the SRC cells were
Figure 2. 5-Aza-2-deoxycytidine treatment increases the inva-
siveness of rat chondrosarcoma cells. Invasiveness was measured
in control SRC cells (SRC Control), SRC cells that were treated for 5
passages with 5-Aza-2-deoxycytidine (SRC 5AZA), and SRC cells 5-with 5
passages Aza-2-deoxycytidine and then grown for 5 additional passages
without treatment (5AZA-STOP). The invasiveness was calculated for all
samples and the results are displayed as experimental sample
compared to the untreated control SRC cells (100% invasion). The bar
represents the average invasion indices of three biologic replicates, and
the error bars represent the standard deviation of the biologic
replicates. ‘*’ Indicates values that are significantly different than the
‘‘SRC Control’’ sample (p,.05).
doi:10.1371/journal.pone.0008340.g002
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PLoS ONE | www.plosone.org 5 December 2009 | Volume 4 | Issue 12 | e8340Figure 3. Heat map of differentially expressed genes between SRC cells treated 5-Aza-2-deoxycytidine and untreated control SRC
cells. Genes with at least a 5-fold difference were selected for analysis using the pathway program Ingenuity. Ingenuity revealed that, of the 977
differentially expressed genes (603 genes upregulated and 374 downregulated), 135 were identified as cancer related. A subset of these cancer related
genes (see Materials andMethods; seeTableS3 forcomplete genelist andexpression values)wasthen used forhierarchicalclustering, andthe resultsof
that clustering are presented in this figure. Each vertical column represents microarray hybridizations from separate individual experiments. Microarray
hybridizations were carried out on SRC cells treated with 5-Aza-2-deoxycytidine for 5 passages (SRC-5-AZA-P6 [1] and [2]), and microarray hybridizations
were also carried out on SRC cells grown for 5 passages without 5-Aza-2-deoxycytidine treatment (SRC-No-Treat-P6 [1], [2], and[3]). ‘*’ Indicates midkine
and ‘**’ indicates sox-2 in the heat map. The color bar corresponds the to the expression level in relative fluorescent units.
doi:10.1371/journal.pone.0008340.g003
DNA Hypomethylation in Cancer
PLoS ONE | www.plosone.org 6 December 2009 | Volume 4 | Issue 12 | e8340treated for 30 days and subsequently grown in vitro for 30 days
without treatment, but these cells did reestablish methylation levels
that were similar to control cells (Figure 1; LINE-1, LINE1-S2,
and Satellite2). These results suggest that 5-Aza-2-deoxycytidine
treated SRC cells more efficiently reestablish hypermethylation in
vitro than in vivo.
Discussion
Aberrant DNA hypermethylation has been observed in a
variety of cancers including chondrosarcoma [37,38,39].
5-Aza-2-deoxycytidine treatment is thought to lead to the
reactivation of aberrantly hypermethylated genes [40], and
treatment of leukemias with 5-Aza-2-deoxycytidine has been
shown to have clinical benefits [7]. However, genome-wide
hypometylation has also been observed in several types of
cancer[8], and it has been suggested that DNA hypomethyla-
tion may play a role in tumorigenesis [10,11]. Although 5-Aza-
2-deoxycytidine does have clinical benefits, one potential
concern with a drug that induces DNA hypomethylation is
the possibility that, in addition to reintroducing the expression
of abnormally silenced genes, it may also lead to the expression
of genes that are normally epigenetically silenced or it may
lead to an increase of illegitimate transcription events [18].
Genome-wide derepression of transcription of genes that are
normally epigenetically silenced is likely to have a dramatic
impact in cancer cells that already possess abnormal genetic,
epigenetic, or gene expression profiles.
In this study, we examined the effect of 5-Aza-2-deoxycytidine-
induced genome-wide hypomethylation on SRC cells in vitro and in
vivo, using pyrosequencing assays. As expected, treatment with 5-
Aza-2-deoxycytidine led to a decrease in the global methylation
levels of SRC cells. This decrease in methylation was accompanied
by an increase in the invasiveness of the SRC cells in vitro.
Subsequent global gene expression analysis revealed that 5-Aza-2-
deoxycytidine treatment leads to (abnormal) expression of several
cancer related genes.
More detailed analysis of two of the cancer related genes,
sox-2 and midkine, confirmed that their expression levels
increased following 5-Aza-2-deoxycytidine treatment. Methyl-
ation analysis of CpG islands at their transcription start site
revealed that these genes were methylated in control cells and
that they lost methylation after treatment with 5-Aza-2-
deoxycytidine. This result suggests that loss of methylation
may play a role in the activation of both sox-2 and midkine in
5-Aza-2-deoxycytidine-treated SRC cells. It is noteworthy that
sox-2 and midkine contain ‘‘intermediate-type’’ CpG islands
[27]. Transcriptional activity of genes with such type of CpG
islands is known to correlate negatively with their level of
methylation[27]. The expression of these genes may, at least in
part, explain the increase in invasiveness following 5-Aza-2-
deoxycytidine treatment, as both sox-2 and midkine may play
roles in tumor progression [41,42,43].
Sox-2 and midkine may also have a function in stem cells.
Midkine is involved in the growth of neuronal stem cells [32], and
the expression of sox-2 has been shown to be an important factor
for restoring somatic cells to a pluripotent state [31]. An intriguing
possibility is that 5-Aza-2-deoxycytidine may induce the expres-
sion of genes or networks that allow the cells to acquire stem cell-
like properties. Pathway analysis of the differentially expressed
genes led to the identification of a network of stem cell related
genes that became upregulated following 5-Aza-2-deoxycytidine
treatment (Figure S5). Based on the network, sox-2 plays a role in
the regulation of Dppa5 [44], Alpha crystallin B [45] and P-
cadherin [46], and this is consistent with the microarray data (see
Figure 3 and Table S3). Although products of these genes may
have functions in stem cells, their role in the SRC cells is not
known. It is important to note that these genes may have
additional cellular functions. For example, besides their putative
roles in stem cells, midkine and Alpha crystallin B may also play a
role in drug resistance [47,48]. These examples demonstrate the
complex nature of gene expression changes that occur following 5-
Aza-2-deoxycytidine treatment.
A number of genes are also downregulated following 5-Aza-2-
deoxycytidine treatment. Among these are genes with diverse
cellular functions (see Figure 3 and Table S3). One potential
explanation for this observation is that 5-Aza-2-deoxycytidine
treatment may lead to the activation of genes that negatively
regulate other genes. These negative regulators may include
protein-coding genes, as well as microRNA genes that could
negatively regulate gene expression [49]. Another intriguing
possibility is that 5-Aza-2-deoxycytidine treatment might lead to
the expression of other noncoding antisense RNAs that could in
turn negatively regulate gene expression [50,51,52,53].
5-Aza-2-deoxycytidine-induced changes in gene expression
had a significant impact on the phenotype of the SRC cells as
tumors derived from 5-Aza-2-deoxycytidine treated cells pro-
duced larger tumors than tumors derived from untreated cells
(Figure 6A and 6B). Tumors derived from 5-Aza-2-deoxycytidine
treated cells had a lower level of methylation (60 days after
tumor induction) than those derived from control untreated cells
(Figure 8 This is a notable observation because in vitro,3 0d a y s
following 5-Aza-2-deoxycytidine removal, the SRC cells had
reestablished a methylation level that was similar to that of
control cells (Figure 1). It is possible that the in vivo
microenvironment may provide more favorable growth condi-
tions that would allow selection and/or propagation of
hypomethylated cells. In vitro cells do not encounter the same
selective pressure as in vivo cells do, and this difference in
selective pressure may provide an explanation as to why the
tumor cells maintain a lower level of methylation.
While it can be speculated that the microenvironment may
exert some selective pressure on the SRC cells in vivo, the possibility
Table 1. Top pathways altered following 5-Aza-2-
deoxycytidine treatment.
Rank
Function
and Diseases p-value #Molecules
1 Cancer 9.84E-06 135
2 Cellular Growth and Proliferation 9.84E-06 68
3 Gastrointestinal Disease 9.84E-06 14
4 Nervous System Development and Function 2.23E-05 28
5 Ophthalmic Disease 1.21E-04 11
6 Cellular Function and Maintenance 3.74E-04 17
7 Reproductive System Development
and Function
7.29E-04 11
8 Reproductive System Disease 7.40E-04 55
9 Cell Cycle 9.11E-04 20
10 Cell Death 1.16E-03 34
The list of genes with a 5-fold difference (977 genes) in gene expression
between untreated SRC control cells and 5-Aza-2-deoxycytidine treated cells
was analyzed using Ingenuity Pathway Analysis software. The top 10 functions
and diseases are shown in the table. The function, its associated p-value, and
the number of molecules in the specific pathway are shown.
doi:10.1371/journal.pone.0008340.t001
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PLoS ONE | www.plosone.org 7 December 2009 | Volume 4 | Issue 12 | e8340Figure 4. Expression and epigenetic analysis of midkine. (A) Quantitative real time PCR analysis of midkine expression in control SRC cells
(SRC Control), SRC cells that were treated for 5 passages with 5-Aza-2-deoxycytidine (SRC 5AZA), and SRC cells 5-with 5 passages Aza-2-deoxycytidine
and then grown for 5 additional passages without treatment (5AZA-STOP). Treatment with 5-Aza-2-deoxycytidine induces midkine expression. Five
passages following 5-Aza-2-deoxycytidine removal the expression of midkine has dropped but it is greater than that of untreated control cells. Bars
represent the average expression of three biologic replicates, and error bars represent the standard deviation of these replicates. ‘*’ Indicates values
that are significantly different than the ‘‘SRC Control’’ sample (p,.05). Note that for graphical representation two different vertical scale bars are
shown; the vertical scale bar on the left corresponds to the SRC Control and SRC 5AZA-STOP samples, and the vertical Scale bar on the right
corresponds with the SRC 5AZA-STOP sample. (B) Schematic representation of analyzed CpG islands in relation to the midkine transcriptional start
site (TSS). Green bars indicate regions that were targeted for bisulfite sequencing. Bisulfite sequencing of midkine CpG Island 1 and CpG Island 2.
Each row indicates an individual cloned sequence. Circles represent CpG sites. Black circles indicate a methylated CpG site and white circles indicate a
unmethylated CpG site. These changes in methylation of the midkine promoter were confirmed by pyrosequencing (Figure S3A). These results
demonstrate that 5-Aza-2-deoxycytidine treatment leads to the hypomethylation of CpG islands that span regions of the rat midkine gene.
doi:10.1371/journal.pone.0008340.g004
DNA Hypomethylation in Cancer
PLoS ONE | www.plosone.org 8 December 2009 | Volume 4 | Issue 12 | e8340Figure 5. Expression and epigenetic analysis of sox-2. (A) Quantitative real time PCR analysis of sox-2 expression in control SRC cells (SRC
Control), SRC cells that were treated for 5 passages with 5-Aza-2-deoxycytidine (SRC 5AZA), and SRC cells 5-with 5 passages Aza-2-deoxycytidine and
then grown for 5 additional passages without treatment (5AZA-STOP). Treatment with 5-Aza-2-deoxycytidine induces sox-2 expression. Five passages
following 5-Aza-2-deoxycytidine removal the expression of sox-2 has dropped. Bars represent the average expression of three biologic replicates, and
error bars represent the standard deviation of these replicates. ‘*’ Indicates values that are significantly different than the ‘‘SRC Control’’ sample
(p,.05). (B) Schematic representation of analyzed CpG islands in relation to the sox-2 transcriptional start site (TSS). Green bars indicate regions that
were targeted for bisulfite sequencing. Bisulfite sequencing of sox-2 CpG Island 47 and CpG Island 154. Each row indicates an individual cloned
sequence. Circles represent CpG sites. Black circles indicate a methylated CpG site and white circles indicate an unmethylated CpG site. CpG 47 Island
was methylated in untreated SRC cells but following 5-Aza-2-deoxycytidine treatment it became hypomethylated. These changes in methylation of
the sox-2 promter were confirmed by pyrosequencing (Figure S3B). CpG Island 154 was not methylated in either control or treated cells (Figure S4).
doi:10.1371/journal.pone.0008340.g005
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PLoS ONE | www.plosone.org 9 December 2009 | Volume 4 | Issue 12 | e8340Figure 6. 5-Aza-2-deoxycytidine treated SRC cells produced larger tumors than untreated SRC cells. (A) In vivo bioluminescent imaging
of SRC cells in nude mice. 5610
6 Control cells [animal a; left] and 5610
6 5-Aza-2-deoxycytidine treated cells [animal B; right] were injected
subcutaneously. This image was collected 6 weeks after tumor induction. This Image corresponds to animal 3a and 3b in Table S5. (B) Summary of in
vivo SRC injections. Tumors induced with 5-Aza-2-deoxycytidine-treated SRC cells produced larger tumors than the tumors induced with SRC control
cells. A linear regression method was applied to analyze tumor weight between two tumor groups (SRC Control and SRC 5AZA) after adjusting for the
number of cells injected. For graphical representation the tumor weights and the number of cells injected was log transformed. p-value is for
comparison of the two tumor groups (SRC Control and SRC 5AZA), and indicates that there is a significant difference in tumor weight between the
two groups. Results are shown for 7 animals with tumors induced from untreated cells (SRC control) and for 7 animals with tumors induced from 5-
Aza-2-deoxycytidine-treated cells (SRC 5AZA). Detailed in vivo tumor summary is presented in Table S5.
doi:10.1371/journal.pone.0008340.g006
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time than that of the cells in vivo. The faster doubling time would
presumably allow the in vitro cells to more quickly regain DNA
methylation, whereas the cells in vivo may have a slower doubling
time and therefore would require more time for the cells to
reestablish the same methylation level that was observed in vitro.
It is important to note that 5-Aza-2-deoxycytidine is not
currently used for the treatment of human chondrosarcoma, and
the treatment schedule presented in this paper was designed for
the treatment of cells in vitro and therefore it does not match a
standard clinical treatment schedule. Consequently, the results
obtained with 5-Aza-2-deoxycytidine may be specific for the SRC
cell line and the conditions of the experiment.
Despite the nontraditional use of 5-Aza-2-deoxycytidine, our
results suggest that genome-wide DNA hypomethylation,
induced by 5-Aza-2-deoxycytidine, may actually promote
certain aspects of tumorigenesis in SRC cells. This observation
may initially seem counterintuitive based on the use of 5-Aza-
2-deoxycytidine as a chemotherapeutic agent, but previous
studies have demonstrated that 5-Aza-2-deoxycytidine can be
mutagenic [54], and that DNA hypomethylation can promote
the formation of tumors [10,11]. Recent studies have also
shown that chromatin modifying agents, including 5-Aza-2-
deoxycytidine, are capable of inducing pluripotency associated
genes [55] and it is possible to speculate that the activation
of pluripotency associated genes may have a substantial
impact on tumor cells. However, further studies are needed
to attain a greater understanding of the effect that these
epigenetic modifying drugs have on tumor cells. Finally,
additional studies are needed to investigate the specific
mechanisms by which genome-wide loss of methylation may
promote tumorigenesis.
Figure 7. Photomicroscopy of histological sections obtained from SRC tumors (20x magnification). (A) Subcutaneous tumor induced from
untreated SRC control cells. (B) Subcutaneous tumor induced from 5-Aza-2-deoxycytidine SRC cells. Approximately 60 days following tumor induction
animals were sacrificed and tumors were removed for histology. Tumors from the SRC control cells and the 5-Aza-2-deoxycytidine cells showed
considerable heterogeneity. There was no clear histological difference between tumors initiated from control cells or treated cells. Low grade (Grade 1) –
Small nuclei with low variation in size and abundant cartilage matrix. Intermediate grade (Grade 2) – Higher cellularity, larger nuclei with increased atypia
and hyperchromasia. High grade (Grade 3) – Pleomorphic cells with greater degree atypia and nuclear size. The SRC cells are stained with Safranin O (red).
doi:10.1371/journal.pone.0008340.g007
Figure 8. Pyrosequencing of LINE and Satellite 1 and 2 in vivo.
Pyrosequencing results are also displayed from tumor samples: tumors
initiated from untreated SRC cells (SRC Control) and tumors initiated
from SRC cells that were treated for 5 passages with 5-Aza-2-
deoxycytidine (SRC 5AZA). Results are shown for 3 SRC Control tumors
and 3 SRC 5AZA tumors. Pyrosequencing assay: LINE1-S1; [2481 CpG’s],
LINE1-S2; [3308 CpG’s], Satellite I [15CpG’s], Satellite II [411 CpG’s]. In all
regions examined by pyrosequencing the SRC 5AZA tumors have a
significantly lower level of methylation than the SRC Control tumors.
Bars represent the average DNA methylation % of three biologic
replicates, and error bars represent the standard deviation of these
replicates. ‘*’ Indicates values that are significantly different than the
‘‘SRC Control’’ sample (p,.05).
doi:10.1371/journal.pone.0008340.g008
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Table S1 Pyrosequencing primer design and PCR conditions
Found at: doi:10.1371/journal.pone.0008340.s001 (0.02 MB
XLS)
Table S2 Bisulfite treated DNA primer design
Found at: doi:10.1371/journal.pone.0008340.s002 (0.04 MB
XLS)
Table S3 5-aza-2-deoxycytidine treatment induces gene expres-
sion changes in the SRC cells
Found at: doi:10.1371/journal.pone.0008340.s003 (0.19 MB
XLS)
Table S4 Top pathways upregulated and downregulated
following 5-Aza-2-deoxycytidine treatment. The list of genes with
a 5-fold difference (977 genes) in gene expression between
untreated SRC control cells and 5-Aza-2-deoxycytidine treated
cells were further separated into lists of upregulated (603 genes) or
downregulated (374 genes) genes. The lists were analyzed using
Ingenuity Pathway Analysis software. The top 10 functions and
diseases are shown in the table. The function, its associated p-
value, and the number of molecules in the specific pathway are
shown.
Found at: doi:10.1371/journal.pone.0008340.s004 (0.28 MB TIF)
Table S5 In vivo: Subcutaneous transplantation of SRC tumor
cells. SRC-MSCV3-LTC Cells were injected into nude mice. The
number of cells injected in a given experiment is listed in the table.
Control cells were grown for 5 passages without any drug
treatment and the cells were injected subcutaneously. Treated cells
were grown for 5 passages in the presence of 5-Aza-2-
deoxycytidine, treatment was removed, and the cells were injected
subcutaneously. Approximately 60 days after subcutaneous cell
injections the animals were sacrificed and the tumors were
collected. Rows in the table represent individual animals. For
each experiment one animal was injected with control cells (A) and
a corresponding animal was injected with 5-Aza-2-deoxycytidine
treated cells (B). The units for surface radiance are photons/sec/
cm2/sr. For certain animals the lungs were saved for histologic
analysis and the detection of tumor cells in the lung is noted in the
table.
Found at: doi:10.1371/journal.pone.0008340.s005 (0.23 MB TIF)
Figure S1 Percent viability of SRC cells following 72 hour and
144 hour incubation with 5-Aza-2-deoxycytidine. (A) Percent
viability of SRC cells 72 hours following treatment with 0, 0.1,
0.3, 1.0, 3.0, 10, 30,100, and 300 uM 5-Aza-2-deoxycytidine. (B)
Percent viability of SRC cells following treatment with 0, 0.1, 1.0,
10, and 100 uM 5-Aza-2-deoxycytidine. Viability is displayed as
the % of the control sample as previously described [22]. Each
point on the graph represents the average viability of three biologic
replicates, and the error bars represent the standard deviation of
the biologic replicates. ‘‘***’’ indicates a significant difference
between a given sample and the control sample (0.0 uM, no
treatment).
Found at: doi:10.1371/journal.pone.0008340.s006 (0.32 MB TIF)
Figure S2 Macrometastasis detected in the lungs of mice
injected with 5-Aza-2-deoxycytidine treated SRC cells. Macro-
metastases were detected in 3 of 9 animals injected with 5-Aza-2-
deoxycytidine treated cells, but no macrometastases were detected
in the lungs of mice injected with untreated cells. Metastases of
varying size were detected in the in the lungs of the same animal.
The SRC tumor cells form nodules of different sizes and resemble
hyaline cartilage. Lungs from 3 separate mice are displayed in the
figure.
Found at: doi:10.1371/journal.pone.0008340.s007 (2.22 MB TIF)
Figure S3 Pyrosequencing of the midkine and sox-2 promoter.
CpG sites in the midkine(A) and sox-2 (B) promoter sequence are
methylated in untreated SRC cells but following 5-Aza-2-deoxycy-
tidine treatment they become hypomethylated. The promoter
regions of midkine and sox-2 were analyzed for DNA methylation
status. Pyrosequencing was used to analyze bisulfite treated DNA
with primers specific for midkine or sox-2. The bar represents the
average DNA methylation of technical replicates, and the error bars
represent the standard deviation of the technical replicates. ‘*’
Indicates that the values are significantly different than the ‘‘SRC
Control’’ sample (p,.05). Five CpG sites were examined with the
midkine promoter analysis. Eight CpG sites were examined in the
sox-2 analysis. The pyrosequencing analysis for midkine promoter
was carried out using the following primers: MDK-2-c-F1: biotin/
GTTAAGGTTTTTTTTGTTTTTAGAAT; MDK-2-c-F1: TA-
AATAACACAAACACAAAAAATCC; (Sequencing primer)
MDK-2-c-S1: ACAAACACAAAAATCCC. The pyrosequencing
analysis for sox-2 promoter was carried out using the following
primers: Sox_2_CpG47-3-F1: ttgtgttaattagtaggggtaatg; Sox_2_
CpG47-3-R1: biotin/CAACTTCCTAACATCCCA; (Sequencing
primer) Sox_2_CpG47-3-S1: TGTGTTAATTAGTAGGGG-
TA.
Found at: doi:10.1371/journal.pone.0008340.s008 (0.54 MB TIF)
Figure S4 Epigenetic analysis of sox-2. Bisulfite sequencing of
sox-2 CpG Island 154. CpG Island 154 was not methylated in
either control or treated cells. Schematic representation of
analyzed CpG islands in relation to the sox-2 transcriptional start
site (TSS). Green bars indicate regions that were targeted for
bisulfite sequencing. Each row indicates an individual cloned
sequence. Circles represent CpG sites. Black circles indicate a
methylated CpG site and white circles indicate an unmethylated
CpG site. See Figure 5B for sox-2 CpG Island 47 methylation
analysis.
Found at: doi:10.1371/journal.pone.0008340.s009 (0.53 MB TIF)
Figure S5 Identification of Sox-2 regulated genes. (A) Genes
with a 5-fold difference between control and 5-Aza-2-deoxycyti-
dine treated cells were imported into the pathway program
GeneGO. GenGO identified a network whereby sox-2 putatively
activates the expression of Dppa5, Alpha crystallin B, and P-
cadherin. (B) Upregulation of Dppa5, CyraB, Cdh3, and Sox2
following 5-aza-2-deoxycytidine treatment. Closer examination of
the expression analysis indicated that the genes, displayed in
Figure S4A, become upregulated following 5-Aza-2-deoxycytidine
treatment. The relative expression ratios of Dppa5, Alpha
crystallin B, and P-cadherin are similar to that of sox-2, suggesting
that sox-2 may play a role in the regulation of these genes.
Expression values extracted from normalized microarray data.
Found at: doi:10.1371/journal.pone.0008340.s010 (0.09 MB TIF)
Acknowledgments
We thank Dr. Nikia Laurie and Carl Radosevich for their assistance with
experimental design and technical support with the cell viability assays.
Author Contributions
Conceived and designed the experiments: CAH HX FFC EFV EAS MFB
MJH MBS. Performed the experiments: CAH HX FFC EFV EAS.
Analyzed the data: CAH HX FFC EAS STS JB DW MFB MBS.
Contributed reagents/materials/analysis tools: CAH HX FFC EFV EAS
JB DW MFB MJH MBS. Wrote the paper: CAH. Assisted with writing of
the paper: HX MBS. Assisted with editing of manuscript: FFC STS JB
MFB MJCH. Assisted with figure preparation: JB. Statistical analysis of
data: DW.
DNA Hypomethylation in Cancer
PLoS ONE | www.plosone.org 12 December 2009 | Volume 4 | Issue 12 | e8340References
1. Brena RM, Costello JF (2007) Genome-epigenome interactions in cancer. Hum
Mol Genet 16 Spec No 1: R96–105.
2. Mund C, Brueckner B, Lyko F (2006) Reactivation of epigenetically silenced
genes by DNA methyltransferase inhibitors: basic concepts and clinical
applications. Epigenetics 1: 7–13.
3. Chen L, MacMillan AM, Chang W, Ezaz-Nikpay K, Lane WS, et al. (1991)
Direct identification of the active-site nucleophile in a DNA (cytosine-5)-
methyltransferase. Biochemistry 30: 11018–11025.
4. Santi DV, Norment A, Garrett CE (1984) Covalent bond formation between a
DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl
Acad Sci U S A 81: 6993–6997.
5. Mund C, Hackanson B, Stresemann C, Lubbert M, Lyko F (2005)
Characterization of DNA demethylation effects induced by 5-Aza-29-deoxycy-
tidine in patients with myelodysplastic syndrome. Cancer Res 65: 7086–7090.
6. Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, et al. (2006) DNA
methylation changes after 5-aza-29-deoxycytidine therapy in patients with
leukemia. Cancer Res 66: 5495–5503.
7. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, et al. (2004) Phase
1 study of low-dose prolonged exposure schedules of the hypomethylating agent
5-aza-29-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103:
1635–1640.
8. Hoffmann MJ, Schulz WA (2005) Causes and consequences of DNA
hypomethylation in human cancer. Biochem Cell Biol 83: 296–321.
9. Fraga MF, Herranz M, Espada J, Ballestar E, Paz MF, et al. (2004) A mouse skin
multistage carcinogenesis model reflects the aberrant DNA methylation patterns
of human tumors. Cancer Res 64: 5527–5534.
10. Eden A, Gaudet F, Waghmare A, Jaenisch R (2003) Chromosomal instability
and tumors promoted by DNA hypomethylation. Science 300: 455.
11. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, et al. (2003)
Induction of tumors in mice by genomic hypomethylation. Science 300:
489–492.
12. Choi HU, Meyer K, Swarm R (1971) Mucopolysaccharide and protein–
polysaccharideofatransplantable ratchondrosarcoma. ProcNatl Acad Sci USA
68: 877–879.
13. King KB, Kimura JH (2003) The establishment and characterization of an
immortal cell line with a stable chondrocytic phenotype. J Cell Biochem 89:
992–1004.
14. Maibenco HC, Krehbiel RH, Nelson D (1967) Transplantable osteogenic tumor
in the rat. Cancer Res 27: 362–366.
15. Morcuende JA, Huang XD, Stevens J, Kucaba TA, Brown B, et al. (2002)
Identification and initial characterization of 6,000 expressed sequenced tags
(ESTs) from rat normal-growing cartilage and swarm rat chondrosarcoma
cDNA libraries. Iowa Orthop J 22: 28–34.
16. Stevens JW, Patil SR, Jordan DK, Kimura JH, Morcuende JA (2005)
Cytogenetics of swarm rat chondrosarcoma. Iowa Orthop J 25: 135–140.
17. Costa FF, Paixao VA, Cavalher FP, Ribeiro KB, Cunha IW, et al. (2006)
SATR-1 hypomethylation is a common and early event in breast cancer. Cancer
Genet Cytogenet 165: 135–143.
18. Stresemann C, Lyko F (2008) Modes of action of the DNA methyltransferase
inhibitors azacytidine and decitabine. Int J Cancer 123: 8–13.
19. Kadomatsu K, Muramatsu T (2004) Midkine and pleiotrophin in neural
development and cancer. Cancer Lett 204: 127–143.
20. Niwa H (2007) How is pluripotency determined and maintained? Development
134: 635–646.
21. Rose JK, Gallione CJ (1981) Nucleotide sequences of the mRNA’s encoding the
vesicular stomatitis virus G and M proteins determined from cDNA clones
containing the complete coding regions. J Virol 39: 519–528.
22. Qin T, Youssef EM, Jelinek J, Chen R, Yang AS, et al. (2007) Effect of
cytarabine and decitabine in combination in human leukemic cell lines. Clin
Cancer Res 13: 4225–4232.
23. Zhu LJ, Altmann SW (2005) mRNA and 18S-RNA coapplication-reverse
transcription for quantitative gene expression analysis. Anal Biochem 345:
102–109.
24. Pfaffl MW (2001) A new mathematical model for relative quantification in real-
time RT-PCR. Nucleic Acids Res 29: e45.
25. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, et al. (2002) The
human genome browser at UCSC. Genome Res 12: 996–1006.
26. Takai D, Jones PA (2003) The CpG island searcher: a new WWW resource. In
Silico Biol 3: 235–240.
27. Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, et al. (2007)
Distribution, silencing potential and evolutionary impact of promoter DNA
methylation in the human genome. Nat Genet 39: 457–466.
28. Hendrix MJ, Seftor EA, Seftor RE, Fidler IJ (1987) A simple quantitative assay
for studying the invasive potential of high and low human metastatic variants.
Cancer Lett 38: 137–147.
29. Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, et al. (2004)
Biological significance of focal adhesion kinase in ovarian cancer: role in
migration and invasion. Am J Pathol 165: 1087–1095.
30. Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, et al. (2004) A simple
method for estimating global DNA methylation using bisulfite PCR of repetitive
DNA elements. Nucleic Acids Res 32: e38.
31. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, et al. (2008) Reprogramming
of human somatic cells to pluripotency with defined factors. Nature 451:
141–146.
32. Zou P, Muramatsu H, Miyata T, Muramatsu T (2006) Midkine, a heparin-
binding growth factor, is expressed in neural precursor cells and promotes their
growth. J Neurochem 99: 1470–1479.
33. Soderstrom M, Aro HT, Ahonen M, Johansson N, Aho A, et al. (2001)
Expression of matrix metalloproteinases and tissue inhibitors of metalloprotei-
nases in human chondrosarcomas. Apmis 109: 305–315.
34. Soderstrom M, Ekfors T, Bohling T, Aho A, Aro HT, et al. (2001) Cysteine
proteinases in chondrosarcomas. Matrix Biol 19: 717–725.
35. Aigner T (2002) Towards a new understanding and classification of
chondrogenic neoplasias of the skeleton–biochemistry and cell biology of
chondrosarcoma and its variants. Virchows Arch 441: 219–230.
36. Lee FY, Mankin HJ, Fondren G, Gebhardt MC, Springfield DS, et al. (1999)
Chondrosarcoma of bone: an assessment of outcome. J Bone Joint Surg Am 81:
326–338.
37. Asp J, Inerot S, Block JA, Lindahl A (2001) Alterations in the regulatory pathway
involving p16, pRb and cdk4 in human chondrosarcoma. J Orthop Res 19:
149–154.
38. Asp J, Sangiorgi L, Inerot SE, Lindahl A, Molendini L, et al. (2000) Changes of
the p16 gene but not the p53 gene in human chondrosarcoma tissues.
Int J Cancer 85: 782–786.
39. Ropke M, Boltze C, Neumann HW, Roessner A, Schneider-Stock R (2003)
Genetic and epigenetic alterations in tumor progression in a dedifferentiated
chondrosarcoma. Pathol Res Pract 199: 437–444.
40. Karpf AR, Jones DA (2002) Reactivating the expression of methylation silenced
genes in human cancer. Oncogene 21: 5496–5503.
41. Kato M, Maeta H, Kato S, Shinozawa T, Terada T (2000) Immunohisto-
chemical and in situ hybridization analyses of midkine expression in thyroid
papillary carcinoma. Mod Pathol 13: 1060–1065.
42. Sanada Y, Yoshida K, Konishi K, Oeda M, Ohara M, et al. (2006) Expression
of gastric mucin MUC5AC and gastric transcription factor SOX2 in ampulla of
vater adenocarcinoma: comparison between expression patterns and histologic
subtypes. Oncol Rep 15: 1157–1161.
43. Tanabe K, Matsumoto M, Ikematsu S, Nagase S, Hatakeyama A, et al. (2008)
Midkine and its clinical significance in endometrial carcinoma. Cancer Sci 99:
1125–1130.
44. Tanaka TS, Kunath T, Kimber WL, Jaradat SA, Stagg CA, et al. (2002) Gene
expression profiling of embryo-derived stem cells reveals candidate genes
associated with pluripotency and lineage specificity. Genome Res 12:
1921–1928.
45. Ijichi N, Tsujimoto N, Iwaki T, Fukumaki Y, Iwaki A (2004) Distal Sox binding
elements of the alphaB-crystallin gene show lens enhancer activity in transgenic
mouse embryos. J Biochem 135: 413–420.
46. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, et al. (2005) Core
transcriptional regulatory circuitry in human embryonic stem cells. Cell 122:
947–956.
47. Ivanov O, Chen F, Wiley EL, Keswani A, Diaz LK, et al. (2008) alphaB-
crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in
breast cancer. Breast Cancer Res Treat 111: 411–417.
48. Mirkin BL, Clark S, Zheng X, Chu F, White BD, et al. (2005) Identification of
midkine as a mediator for intercellular transfer of drug resistance. Oncogene 24:
4965–4974.
49. Lujambio A, Calin GA, Villanueva A, Ropero S, Sanchez-Cespedes M, et al.
(2008) A microRNA DNA methylation signature for human cancer metastasis.
Proc Natl Acad Sci U S A 105: 13556–13561.
50. Cayre A, Rossignol F, Clottes E, Penault-Llorca F (2003) aHIF but not HIF-
1alpha transcript is a poor prognostic marker in human breast cancer. Breast
Cancer Res 5: R223–230.
51. Stuart JJ, Egry LA, Wong GH, Kaspar RL (2000) The 39 UTR of human
MnSOD mRNA hybridizes to a small cytoplasmic RNA and inhibits gene
expression. Biochem Biophys Res Commun 274: 641–648.
52. Tufarelli C, Stanley JA, Garrick D, Sharpe JA, Ayyub H, et al. (2003)
Transcription of antisense RNA leading to gene silencing and methylation as a
novel cause of human genetic disease. Nat Genet 34: 157–165.
53. Costa FF (2008) Non-coding RNAs, epigenetics and complexity. Gene 410:
9–17.
54. Jackson-Grusby L, Laird PW, Magge SN, Moeller BJ, Jaenisch R (1997)
Mutagenicity of 5-aza-29-deoxycytidine is mediated by the mammalian DNA
methyltransferase. Proc Natl Acad Sci U S A 94: 4681–4685.
55. Ruau D, Ensenat-Waser R, Dinger TC, Vallabhapurapu DS, Rolletschek A,
et al. (2008) Pluripotency associated genes are reactivated by chromatin-
modifying agents in neurosphere cells. Stem Cells 26: 920–926.
DNA Hypomethylation in Cancer
PLoS ONE | www.plosone.org 13 December 2009 | Volume 4 | Issue 12 | e8340